Immune checkpoint inhibitors (ICIs) have dramatically enhanced the treatment outcomes for
diverse malignancies. Yet, only 15–60% of patients respond significantly. Therefore …

Lung cancer remains the first cause of cancer-related death despite many therapeutic
innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily …

Aim A programmed death 1 (PD-1) inhibitor coupled with radiotherapy and antiangiogenic
therapy is a potential therapeutic strategy for advanced hepatocellular carcinoma (HCC). We …

Programmed cell death protein ligand‐1 (PD‐L1) expression in non‐small cell lung cancer
(NSCLC) tumors guides treatment selection. PD‐L1 expression in circulating tumor cells …

Background The main types of PD-L1 in the blood include soluble PD-L1 (sPD-L1),
exosomal PD-L1 (exoPD-L1), and PD-L1 in circulating tumor cells (CTCs). However, the …

Non-small cell lung cancer (NSCLC) is one of the deadliest diseases worldwide. Tissue
biopsy is the current gold standard for the diagnosis and molecular profiling of NSCLC …

CXCR4, JUNB and PD-L1 are implicated in cancer progression and metastasis. The current
study investigated these biomarkers in CTCs isolated from metastatic prostate cancer …

This review is an overview of the current knowledge regarding circulating tumour cells
(CTCs), which are potentially the most lethal type of cancer cell, and may be a key …

Background In the last decade, immune checkpoint inhibitors have revolutionized the
treatment of metastatic nonsmall cell lung cancer without oncogenic addiction. Currently …

The PD-1/PD-L1 axis provides CTCs an escape route from the immune system.
Phosphorylation of the ribosomal protein S6 is implicated in the same pathway, following …